ASH 2019 | MANIFEST study of CPI-0610 in myelofibrosis
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, presents the results of the phase 2 MANIFEST study of CPI-0610, an oral BET inhibitor, as a monotherapy or in addition to ruxolitinib, in refractory or intolerant advanced myelofibrosis. Preliminary data indicate that CPI-0610 alone or as an add-on is generally well-tolerated and provides clinical benefits, and the study is being further expanded. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up